AR101840A1 - Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene - Google Patents

Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene

Info

Publication number
AR101840A1
AR101840A1 ARP150102901A ARP150102901A AR101840A1 AR 101840 A1 AR101840 A1 AR 101840A1 AR P150102901 A ARP150102901 A AR P150102901A AR P150102901 A ARP150102901 A AR P150102901A AR 101840 A1 AR101840 A1 AR 101840A1
Authority
AR
Argentina
Prior art keywords
protein
human papillomavirus
seq
gene
gene encoding
Prior art date
Application number
ARP150102901A
Other languages
English (en)
Inventor
Glueck Reinhard
Giannino Viviana
Gupta Gaurav
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of AR101840A1 publication Critical patent/AR101840A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicación 1: Un gen aislado que codifica la proteína de la cápside mayor del virus del papiloma humano, caracterizado porque dicho gen se selecciona entre SEQ ID Nº 2, SEQ ID Nº 3, SEQ ID Nº 4 y SEQ ID Nº 5. Reivindicación 2: Un vector que comprende el gen que codifica la proteína de la cápside mayor del virus del papiloma humano, caracterizado porque dicho gen se selecciona entre SEQ ID Nº 2, SEQ ID Nº 3, SEQ ID Nº 4, SEQ ID Nº 5, y su combinación. Reivindicación 6: Una célula huésped caracterizada porque comprende el vector tal como se reivindica en la reivindicación 2. Reivindicación 11: Una vacuna contra el virus del papiloma humano, caracterizada porque comprende al menos un gen que codifica la proteína del cápside entre las reivindicadas en la reivindicación 1, que puede generar una respuesta inmunitaria contra el antígeno del HPV. Reivindicación 16: Un método para preparar la vacuna contra el virus del papiloma humano tal como se reivindica en la reivindicación 11, caracterizado porque comprende los siguientes pasos: a) síntesis del gen que codifica la proteína de la cápside mayor del virus del papiloma humano; b) construcción del vector de expresión para el gen que codifica la proteína de la cápside mayor del virus del papiloma humano; c) selección del clon con un número alto de copias del gen transformado de dicha proteína del virus del papiloma humano; d) análisis de expresión del gen transformado de dicha proteína del virus del papiloma humano; e) purificación de la proteína codificada por el gen de dicha proteína del virus del papiloma humano; f) preparación de solución a granel de VLPs de dicha proteína del virus del papiloma humano; g) caracterización de dicha proteína en la célula huésped; h) preparación de la vacuna que contiene dicha proteína del virus del papiloma humano.
ARP150102901A 2014-09-11 2015-09-11 Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene AR101840A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2905MU2014 2014-09-11

Publications (1)

Publication Number Publication Date
AR101840A1 true AR101840A1 (es) 2017-01-18

Family

ID=54843870

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102901A AR101840A1 (es) 2014-09-11 2015-09-11 Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene

Country Status (10)

Country Link
EP (1) EP3191505A2 (es)
JP (1) JP2017528137A (es)
CN (1) CN107002085A (es)
AR (1) AR101840A1 (es)
AU (1) AU2015313756A1 (es)
BR (1) BR112017004181A2 (es)
CA (1) CA2958222A1 (es)
EA (1) EA201790365A1 (es)
MA (1) MA40624A (es)
WO (1) WO2016038625A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111154777B (zh) * 2014-02-18 2023-08-15 上海泽润生物科技有限公司 重组人乳头瘤病毒蛋白表达
EP3365006A1 (en) 2015-10-19 2018-08-29 Cadila Healthcare Limited New adjuvant and vaccine composition containing the same
CN109750049B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒52亚型蛋白表达
EP3710468A1 (en) 2017-11-14 2020-09-23 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Non-human papillomaviruses for gene delivery in vitro and in vivo
US11389519B2 (en) * 2018-06-11 2022-07-19 Inventprise, Llc Virus-like particle conjugates
BR102020006846A2 (pt) * 2020-04-03 2021-12-07 Imunoscan Engenharia Molecular Ltda Peptídeos sintéticos miméticos a proteína l1 do hpv, método de diagnóstico de hpv, sistema de diagnóstico de hpv, composição farmacêutica e uso dos mesmos no tratamento ou profilaxia do hpv

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213185T3 (es) * 1995-11-15 2004-08-16 MERCK & CO., INC. Particulas de tipo virus hpv11 sinteticas.
ES2216280T3 (es) * 1997-04-08 2004-10-16 MERCK & CO., INC. Formulaciones estabilizadas de papilomavirus humano.
EP1700911B1 (en) * 1997-09-05 2016-04-06 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
JP4769247B2 (ja) * 2004-06-18 2011-09-07 インディアン・イムノロジカルズ・リミテッド ヒトパピローマウイルス１６型に対するＳａｌｍｏｎｅｌｌａワクチン株に関するコドン最適化されたＨＰＶ１６Ｌ１
EP2223933B1 (en) * 2007-11-23 2016-01-27 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein l1 of human papilloma viruses
CN101487009B (zh) * 2008-01-15 2012-11-21 上海泽润生物科技有限公司 用毕赤酵母表达系统制备抗人乳头瘤病毒16型感染的疫苗的方法
JP6022159B2 (ja) * 2008-07-31 2016-11-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗ｈｐｖワクチン
WO2010147268A1 (ko) * 2009-06-19 2010-12-23 아이진 주식회사 자궁경부암 백신
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
AU2012255595A1 (en) * 2011-05-13 2013-12-12 Folia Biotech Inc. Virus-like particles and process for preparing same
JP6050811B2 (ja) * 2011-06-24 2016-12-21 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アルミニウムアジュバントを含むｈｐｖワクチン製剤およびその産生方法
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
CN103667319B (zh) * 2012-09-10 2017-09-26 同济大学 抗人乳头瘤病毒的三价疫苗及其制法和用途

Also Published As

Publication number Publication date
AU2015313756A1 (en) 2017-03-09
EA201790365A1 (ru) 2017-07-31
WO2016038625A3 (en) 2016-04-28
CN107002085A (zh) 2017-08-01
BR112017004181A2 (pt) 2017-12-05
WO2016038625A2 (en) 2016-03-17
JP2017528137A (ja) 2017-09-28
MA40624A (fr) 2016-03-17
EP3191505A2 (en) 2017-07-19
CA2958222A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
AR101840A1 (es) Antígenos del virus del papiloma humano superiores con propiedades inmunológicas superiores, y vacuna que los contiene
CO2018005265A2 (es) Vacunas de ácido nucleico para el virus varicela-zóster
PH12017500727A1 (en) Modified virus-like particles of cmv
MX352974B (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
CO2017004838A2 (es) Vacunas terapéuticas contra el vph16
PH12015502790A1 (en) Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof
AR102006A1 (es) Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
PH12019500591A1 (en) Canine adenovirus vectors
AR101468A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
PH12019500578A1 (en) New promoters
PH12019500557A1 (en) New ehv insertion site orf70
CY1118704T1 (el) Ανθρωπινος πληθυσμος βλαστοκυτταρων του τραχηλου της μητρας και χρησεις αυτου
NZ719934A (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
MX2013013228A (es) Particulas similares a virus y proceso para prepararlas.
PH12020500526A1 (en) Paramyxoviridae expression system
MX2019007924A (es) Vacunas contra la influenza.
EA202092164A1 (ru) Новый ehv с инактивированным ul18 и/или ul8
AR092939A1 (es) Vacuna contra cooperia
WO2012001196A3 (es) Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos

Legal Events

Date Code Title Description
FB Suspension of granting procedure